julie vose, md, on management of common toxicities with car-t therapies
Published 5 years ago • 35 plays • Length 0:44Download video MP4
Download video MP3
Similar videos
-
0:49
julie vose, md, on if car-t therapies are showing impressive results in lymphoma
-
0:37
julie vose, md, discusses improvements made in the delivery of car-t therapies in lymphoma
-
4:54
dr. julie vose discusses car t-cell therapy and the fred & pamela buffett cancer center
-
0:37
julie vose, md, tells us about results of the augment study in relapsed/refractory indolent nhl
-
0:21
julie vose, md, discusses whether polatuzumab improves outcomes in dlbcl patients
-
2:22
combining car-ts & bispecific antibodies
-
4:13
julie gralow, md, offers opinion on immunotherapy treatment trends in the management of tnbc
-
2:35
julie gralow, md, elaborates on the issue of resistance to endocrine therapies
-
3:43
the future of car-t therapy
-
0:54
zev wainberg, md, speculates on the role of bemarituzumab in other fgfr2b-positive tumor types
-
2:08
car t-cell therapy: co-operation could lead to unprecedented levels of efficacy
-
1:06
carl june, md on car t-cell therapy
-
1:34
car t-cell immunotherapy
-
1:40
julie gralow, md, elaborates on how to differentiate cdk4/6 inhibitors
-
2:21
car t-cell therapy: what clinicians need to know about managing the aes
-
0:52
the future of car t-cell therapy for aml
-
0:48
julie brahmer, md, on the level of pd-l1 expression in selecting the appropriate agent in nsclc
-
0:44
what is car t-cell therapy?
-
1:22
car t-cells in hemonc: where do we stand?